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Background: In the area of omics and translational bio(medical)sciences, there is an increasing need to integrate,
normalize, analyze, store and protect genomics data. Large datasets and scientific knowledge are rationally
combined into valuable clinical information that ultimately will benefit human healthcare and are en route to
clinical practice. Data from biomarker discovery and Next Generation Sequencing (NGS) are very valuable and will
combine in comprehensive analyses to stratify medicine and guide therapy planning and ultimately benefit
patients. However, the combination into useful and applicable information and knowledge is not trivial.
NGS in personalized medicine: Personalized medicine generally promises to result in both higher quality in
treatment for individual patients and in lower costs in health care since patients will be offered only such therapies
that are more effective for them and treatments that will not be safe or effective will be avoided. Recent
advancements in biomedical and genomic sciences have paved the way to translate such research into clinical
practice and health policies. However, the move towards greater personalization of medicine also comes along
with challenges in the development of novel diagnostic and therapeutic tools in a complex framework that
assumes that the use of genomic information is part of a translational continuum, which spans from basic to
clinical research, preclinical and clinical trials, to policy research and the analysis of health and economic outcomes.
The use of next-generation genomic technologies to improve the quality of life and efficiency of healthcare
delivered to patients has become a mainstay theme in the field as benefits derived from such approaches include
reducing a patient’s need to go through ineffective therapies, lowering side- and off-target effects of drugs,
prescribing prophylactic therapies before acute exacerbations, and reducing expenditures.
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Economic challenges: As such, personalized medicine promises to increase the quality of clinical care and, in
some cases, to decrease health care costs. Besides the scientific challenges, there are several economic hurdles. For
instance, healthcare providers need to know, whether the approach of personalized healthcare is affordable and
worth the expenses. In addition, the economic rationale of personalized healthcare includes not only the reduction
of the high expense of hospitalizations, the predictive diagnostics that will help to reduce cost through prevention
or the increased efficacy of personalized therapies needs to offset prices of drugs. There are also several factors that
influence payer adoption, coverage and reimbursement; the strength of evidence drives payers‘ decisions about
coverage and reimbursement, varies widely depending on the personalized healthcare technology applied and
regulation and cost-effectiveness seem to be increasingly associated with reimbursement, which is strongly
influenced by professional society guidelines. In general, we see the following main obstacles to the advancement
of personalized medicine: (i) the scientific challenges (a poor understanding of molecular mechanisms or a lack of
molecular markers associated with some diseases, for example), (ii) the economic challenges (poorly aligned
incentives), and (iii) operational issues in public healthcare systems. The operational issues can often be largely
resolved within a particular stakeholder group, but correcting the incentive structure and modifying the
relationships between stakeholders is more complex.
En route to clinical practice: This article focuses on the scientific difficulties that remain to translate genomics
technologies into clinical practice and reviews recent technological advances in genomics and the challenges and
potential benefits of translating this knowledge into clinical practice, with a particular focus on their applications in
oncology.
Keywords: Biomarkers, Bioinformatics, Cancer, Genomics, Next-generation sequencing, Personalized medicine,
Economics, EthicsBackground
Next-generation sequencing (NGS) is revolutionizing the
way of genomic-scale biological research, and its effects
are starting to translate into the clinic. In this sense, the
comprehensive sequencing of the genome, epigenome
and transcriptomes of cancers and corresponding “nor-
mal” (germ-line) DNA are heralding the start of perso-
nalized medical genomics. The promise of truly
personalized medicine and individualized treatments is
certainly appealing, however, several issues must be
resolved before NGS will be adopted as a routine appli-
cation in the clinic and for patients. Among such issues
are the lack of integrated data, the need for relevant
methodologies and research frameworks, and the clinical
complexities of genome-based diagnostics and therapeu-
tics. In personalized genomic medicines, pharmacogen-
omics involves the study of analyzing the individual
variations in drug response; pharmacogenetics involves
the analysis of genetic variation in drug metabolism.
Contemporary studies increasingly involve pathway and
network analyses that include both pharmacokinetics, i.
e. factors that influence the concentration of a drug
reaching its target, and pharmacodynamics, i.e. factors
associated with the drug target, as well as genome-wide
association studies (GWAS) approaches. In regard to the
technology foundations, high-throughput tools for nu-
cleic acid characterization provide the means to conduct
comprehensive analyses of all alterations in a patient’s
genome. Together with the rapid developments inhuman genomics, these disciplines move towards a
system-based translational interface in pathophysiology,
bringing genomic studies into the clinic. This further
leads to the identification of new targets and novel bio-
markers for both diagnostics and therapeutics. To trans-
late biomarker- and NGS-technology-based research
into clinical practice, diagnostics is key. The goal is a tai-
lored approach to treatment based on the molecular
analysis of genes, proteins, and metabolites. Yet, al-
though this approach has generated much excitement,
only a few personalized-medicine tests have achieved
high levels of clinical adoption and are mostly in the
field of oncology. To better understand the challenges to
the development and acceptance of personalized medi-
cine it is important to analyze the current technologies
and complement this information with a (micro)eco-
nomic view on the broad stakeholder issues in “P4 medi-
cine”, which is predictive, personalized, preventive, and
participatory medicine.
This personalized medicine will be fueled by systems
approaches to disease, emerging technologies and novel
analytical tools, including novel tools in bioinformatics,
data analysis and integration of algorithm development.
Next-generation sequencing technologies
Today, sequencers can analyze hundreds of millions of
DNA fragments per run, compared with 1 to 384 DNA
fragments in traditional sequencing methods. Even the
read-lengths obtained with the new sequencing methods
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sequencing method (up to 250 nucleotides vs. > 1000
nucleotides), the volume of sequence produced is much
higher. Currently, several major sequencing platforms
are available for next-generation sequencing (NGS), i.e.
the 454 Life Sciences (www.454lifesciences.com) (Gen-
ome Sequencer™, GS junior) (454 Life Sciences, 2011),
the SOLiD™ technology from Life Technologies (5500
series Genetic Analysis Systems) (www.lifetechnologies.
com) and the sequencing by synthesis (SBS) technology
(Genome Analyzer™, HiSeq 1000/2000, MiSeq, HiS-
canSQ) from Illumina (www.illumina.com). All these
technologies share the same basic principles: The Deso-
xyribonucleic Acid (DNA) of interest is ligated to two
adaptor sequences and immobilized on beads. Subse-
quently, Polymerase Chain Reaction (PCR) amplifies the
signal from individual DNA fragments via the adapter
sequences and the amplified signal, from “beads” in the
SOLiD system or from “clusters” in the Genome
Analyzer, is analyzed using labeled nucleotides. Digital
images are captured and analyzed to determine the indi-
vidual nucleotides in the captured DNA.
Very recently, new players have emerged in the race
toward the US $1,000 genome, among them Pacific Bios-
ciences’ single molecule real time (SMRT™) sequencing
technology and the semiconductor technology offered in
the Ion Torrent PGM™ system (www.iontorrent.com).
In the DNA sequencing process, the PacBio RS system
uses advanced collection optics to record light pulses
emitted as a byproduct of nucleotide incorporation;
algorithms translate these signals into an A, C, G or T
base call (www.pacificbio.com). The Personal Genome
Machine from Ion Torrent (www.iontorrent.com) uses a
massively parallel array of proprietary semiconductor
sensors to perform direct real-time measurement of the
hydrogen ions produced during DNA replication. A
high-density array of wells on the Ion Semiconductor
Chips provides millions of individual reactors while inte-
grated fluidics allow reagents to flow over the sensor
array. The combination of fluidics, micromachining, and
semiconductor technology enables the direct translation
of genetic information to sequence information (www.
iontorrent.com).
With such new technologies in the field of genomics,
it is anticipated, that the US $1,000 genome will become
reality no later that 2013 (Wolinsky 2007; Thomas
2011). RainDance’s Sequence Enrichment application fo-
cuses on the targeted sequencing of the human genome
using the RainStorm™ microdroplet-based technology
for high-resolution analysis of genetic variations between
individuals. The RainStorm technology utilizes a library
of PCR primers enabling the amplification of hundreds
to thousands of genomic loci in a single tube avoiding
limitations of traditional multiplex hybridization andamplification technologies. RainDance’s application for
sequence enrichment improves target enrichment uni-
formity and reduces the selection bias typically asso-
ciated with targeted sequencing (www.raindancetech.
com).
In regards to analyzing cancer genomes in the context
of personalized medicine, the biggest driver to adopt
NGS technologies has been the rapid decrease in the
costs of sequencing per gigabase. This reduced cost has
allowed for the analysis of cancer genomes at a single-
nucleotide resolution. Nowadays, NGS technologies are
used to identify all types of cancer genomic rearrange-
ments and mutations within a single experiment, includ-
ing large-scale chromosomal aberrations, single-
nucleotide variations, structural variations (SV), small
and large insertions, deletions or translocations or copy
number variations (CNV). To obtain a complete deter-
mination of all kind of aberrations in a patient’s cancer
genome, genomic data can be integrated with epige-
nomic and transcriptomic data. In terms of epigenomics,
changes in DNA methylation, histone modifications or
nucleosome positioning are detected and transcriptomic
analyses focus on fusion genes, allele-specific expression
or expressed mutations of aberrant gene expression pat-
terns. However, such integrated analyses require huge
resources for data generation, integration and interpret-
ation. Individual tumors may accumulate more than
10.000 mutations and rearrangements, with only a small
percentage of those are likely to be oncogenic. There-
fore, large-scale sequencing projects enable to distin-
guish between those mutations that contribute to
tumorigenesis, progression or metastasis, and those that
accumulate in the tumor but do not contribute to
disease.
Such projects further expand the repertoire of drug-
gable targets and enable advancements in the develop-
ment of personalized genomics and individual treatment
plans. In cancer genomics, germ-line tumor DNA from
each individual patient needs to be sequenced to under-
stand the genomic heterogeneity at the single-nucleotide
level. This is also interesting in regards to studying gen-
omic heterogeneity in populations and germ-line varia-
tions and to understand how these may affect response
to treatment, the tolerance to side- and off-target effects,
and drug metabolism.
Furthermore, NGS technologies are of great import-
ance in view of cataloguing normal human genetic varia-
tions like Single Nucleotide Polymorphisms (SNP) or
Structural Variants (SV). Several large-scale projects in-
tend to identify such variations, e.g. the 1000 genomes
project or the database of genomic variants (DGV), to
enable pathological genetic changes to be identified and
to understand their disease relevance. Also, it is import-
ant to study genomes and analyze genetic variations
Figure 1 Clinical studies with biomarkers. More than 50% of all
clinical studies that involve biomarkers are in performed in the field
oncology (www.clinicaltrials.gov, 30.000 studies from 1970 until
February 2011, The Boston Consulting Group analysis).
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from different ethnic backgrounds. This will ensure that
personalized medicine is not restricted to those popula-
tions within which most genomics research has been
conducted to date.
The extraction of knowledge from integrated genomic
data, the comprehensive analysis and its transfer into
healthcare IT systems is fundamental and requires not
only state-of-the-art genomic but also IT infrastructures.
The clinical potential of translational genomics
Biomarkers
Biomarkers are simple molecules describing changes and
alterations both in physiological and structural aspects
of cells and tissues, at different levels from genes to
whole tissues. The National Health Institute has defined
biomarkers as "A characteristic that is objectively mea-
sured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention." Among the
principal appliances of biomarkers to personalized medi-
cine, the important ones are their specificity and sensi-
tivity. This represents a highly attractive characteristic in
revealing a disease predisposition or state, and in pre-
dicting a drug behavior or response to treatment. Add-
itionally, biomarkers are very suitable for drug targeting,
compound development, or for clinical trials evaluation.
In regards to drug development, the utilization of bio-
markers represents a powerful tool at preclinical and
early stages, particularly for treatment design.
Today, several clinical studies include biomarkers with
more than 50% of all clinical studies that include bio-
markers being performed in the field of oncology
(Figure 1); more than 1/3 of all clinical studies in cancer
research include biomarkers (Figure 2).
Genetic tests to predict the susceptibility of an individ-
ual to a certain disease or to identify specific genetic
mutations even though the individual remains un-
affected represents one of the most derivations of perso-
nalized medicine. Also, genetic tests and – as a very new
field – virtual disease-modeling can predict the behavior
of a patient to certain drugs and will lead towards
enhances therapeutics and patient treatment strategies.
Tumor biomarkers are crucial tools for diagnosis, and
can be used to monitor disease progression, predict
prognosis and detect recurrence of disease. They can be
of particular value when it comes to predicting the sur-
vival outcome of patients and in determining the appro-
priate treatment plan and course of therapeutic
intervention. NGS technologies contribute to the devel-
opment of such biomarkers since the large-scale sequen-
cing projects of various tumor types allow the
identification of new candidate biomarkers, including
non-coding Ribonucleic Acids (ncRNAs), microRNAs,aberrantly expressed genes, epigenetic markers or copy-
number variations. Several currently available biomar-
kers lack sensitivity of the specificity to screen for all
kind of tumors. As such, the discovery of markers with
higher specificity for different types of cancer will assist
in personalizing a patient’s treatment plan. The ability to
monitor a treatment response or to detect tumor recur-
rence at early stages is key to ensuring that patients re-
ceive optimal therapy regimens. Genome sequencing of
primary tumors is performed to analyze structural varia-
tions and changes such as translocations and leads
towards the identification of truly personalized biomar-
kers. Once identified by sequencing, structural variants
can be detected in the circulating DNA in plasma sam-
ples by PCR (Leary et al., 2010). Such methods, requiring
only a few milliliters of blood, will potentially allow the
development of very sensitive personalized biomarkers
to monitor disease progression, recurrence and the suc-
cess of the selected therapy.
Personalized medicine
Patients with the same type of a tumor may respond in
many different ways to treatment, given the heterogen-
eity of cancer. The sequencing of tumor cells will iden-
tify potential therapeutic targets or pathways that are
silenced or activated in an individual tumor and, conse-
quently, can be used to identify, which drugs and com-
pounds are most likely to succeed in an individual
patient.
Since many cancer drugs come along with undesirable
and severe side effects, personalized treatments intend
to minimize such effects and may maximize the out-
come for each patient and avoid therapies that will have
none or only little effects on the tumor.
Figure 2 More than 1/3 of all clinical studies in oncology include biomarkers. The graphic illustrates the involvement of biomarkers in
clinical studies, sorted by therapeutic area, with more than 1/3 of all clinical studies in oncology involving biomarkers (www.clinicaltrials.gov,
30.000 studies from 1970 until February 2011, The Boston Consulting Group analysis).
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better patient treatment is achieved through novel and
advanced diagnostic tests that will give a prognosis for
an individual patient in terms of responder or non-
responder to a certain therapy (Figure 3).
Thus, a truly personalized approach in genomic-based
medicine will significantly enhance the quality of life of
cancer patients. Examples for individualized treatments
of cancer include HER2/neu-positive breast cancers that
are treated with the monoclonal antibody trastuzumab
(Herceptin™) and poly(ADP-ribose) polymerase (PARP-)
inhibitors used in clinical trials to treat patients with
BRCA1- or BRCA2-deficient breast cancers (Fong et al.
2009).Figure 3 Better patient treatments through advanced diagnostics and
decision-making to prescribe a specific drug, depending on the patie
medication (VFA Bio).Translating cancer genomic data into biomedical
knowledge
Large-scale cancer genomic projects will identify and
enumerate the frequency of every genetic element of
interest that is altered in its structure in a cancer
genome.
The statistical significance for such alterations is based
on the frequency, which is an important filter to distin-
guish driver from passenger mutations. However, it is
likely that mutations occurring at a very low frequency
also contribute to specific types of cancer. In such cases,
additional experimental evidence is important to identify
low-frequency events as contributors to cancer initiation
or progression (Chin and Gray 2008). Often, multiplepersonalized medicine Diagnostic tests will guide the clinical
nt’s prognosis to be a responder or non-responder to a given
Garcia Martinez de Lecea and Rossbach The HUGO Journal 2012, 6:2 Page 6 of 9
http://www.thehugojournal.com/content/6/1/2genetic alterations contribute to the behavior of any spe-
cific cancer; thus, additional functional analyses are
required to complement the genome annotation. A
prominent example can be found in the ras oncogenes
involved in human cancers. It has been demonstrated
that the mutation status of k-ras dictates the response of
tumors with EGFR mutations to treatment with EGFR
inhibitors and that the complex relations of braf, craf,
and ras in response to selective braf inhibitors (Heidorn
et al., 2010; Poulikakos et al., 2010) confirm that further
functional studies are necessary to exploit knowledge of
somatic mutations. Another level of complexity is added
due to the fact that genes not mutated in cancers may
very well contribute to the survival and progression of
tumors with other genetic aberrations. An example is
the parp1 gene, whose inactivation is synthetically lethal
in breast and ovarian cancers that are deficient of
BRCA1 or BRCA2 (Fong et al., 2009, Fong et al., 2010).
The challenge: progressing genomic technologies
into clinical practice
Technologies and methods
Sequencing-based genomic technologies, which mainly
employ traditional Sanger Sequencing technology (capil-
lary electrophoresis), are not new to the clinical labora-
tory and range from infectious disease to cancer
diagnostics. Like other molecular diagnostics, Sanger Se-
quencing enables the analysis of specific gene sequences
for identifying a pathogenic agent, predicting or moni-
toring disease, selecting treatment options, and deter-
mining a treatment’s efficacy. Examples include the
sequencing of the human immunodeficiency virus (HIV)
to monitor the susceptibility or resistance to HIV anti-
viral medications, the sequencing of the cystic fibrosis
(CF) gene or sequencing of the BRCA1 and BRCA2
genes in breast cancer. NGS-based technologies have a
great potential to identify, classify and analyze disease
sub-types, in particular in the elucidation of the contri-
bution of rare, highly penetrant mutations to the genetic
architecture of complex disorders, for instance in the
monogenic form of morbid obesity and Type 2 diabetes.
Such knowledge is very valuable in the delivery of perso-
nalized medicine
Also, for rare and orphan disease in general, NGS-
and biomarker-based analyses can help to identify rele-
vant loci in disorders and thus might stimulate drug
development in this area.
In oncology, NGS-based systems will allow for the
rapid sequencing of tumor genomes to direct cancer
treatments, pathogen genomes to determine drug resist-
ance, or cell-free DNA to identify chromosomal abnor-
malities in pregnancy, and offer undisputed advantages
over Sanger Sequencing. The time involved to generate
and analyze genomic data in a medical contextrepresents one of the major challenges en route to apply
NGS technologies as a standard tool in clinical practice.
However, as technologies develop and progress, sequen-
cing at a cost of US$ 1,000 might be possible in the near
future. If genomic data feed clinical decision-support
systems to evaluate the best possible therapeutic inter-
vention, then these results should ideally be available
within a short timeframe, i.e. rather within a few days
than weeks. To achieve this, the steps performed during
the analyses, which include library preparation, sequen-
cing runs and the integrated data interpretation, must be
fast, reliable and fully automated. The integrated and
advanced analysis of genomic data comes along with the
collection of such data; automatic analysis software for
detecting somatic mutations is being developed and is
tested for its sensitivity, specificity and accuracy. The
challenge lies in assigning the biological significance of
each somatic mutation and integrating each data type,
viz. genomic, epigenomic or transcriptomic, to predict
the biological impact. The biological understanding of
the human genome is far from complete and although
somatic mutations and aberrations may be detected, the
information would not be informative to the clinicians if
the genes affected have not been studied so far or if the
pathways they are involved in are unknown.
Another challenge is the starting material required to
generate the sequencing libraries. Samples with a limited
amount of starting material, e.g. from core biopsies, are
beyond the scope of the most thorough genomic ana-
lyses. For transcriptomic libraries, typically a depletion
of the ribosomal RNA (rRNA) is required to allow the
signal from expressed genes to be detected and such de-
pletion does not work well with degraded RNA, affecting
mostly formalin-fixed samples. Normal DNA can be
derived from blood samples; however, gene expression
and epigenomic variation differ significantly in different
tissues. Thus, adjacent healthy tissue is required to de-
termine the default and “normal” status of the gene ex-
pression, epigenome and trancriptome. Depending on
the size and location of a specific tumor, this could be
very challenging.
Predictive, preventive, personalized and participatory
medicine
As a result to all current efforts to translate the concepts
of personalized healthcare into the clinic, personalized
medicine will become participatory and this implies pa-
tient decisions about their own health. As a prerequisite,
such a new paradigm requires powerful tools to securely
handle significant amounts of personal information with
the approach introduced as P4 medicine that is predict-
ive, preventive, personalized and participatory. The main
benefits from P4 medicine include enabling the design
of drugs based on proteins and RNAs molecules
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developing therapies that are highly targeted to specific
diseases in order to maximize the effects of therapeutic
interventions while minimizing side-effects or damaging
healthy tissues. Avoiding trial and error phases through
better and truly personalized drugs, using genetic pro-
files to identify the best possible drug and therapy for a
given patient and reducing adverse effects are instances
of personalized medicine goals, will benefit not only
patients, but the public healthcare systems in general.
The P4 medical approach will also help to select the
right drug for the right patient at the right time, avoid-
ing that valuable drugs are prescribed to unsusceptible
patients and preventing potentially harmful side-effects
(Figure 4).
In this regard, novel genome-based diagnostic tech-
nologies offer a significant progress in medical practice
in comparison with the current prevention methods; a
combination of genetic knowledge and clinical studies is
expected to impart a significant advance toward prevent-
ive medicine and subsequent prospective medicine.
Genomic literacy: education and counseling
Large-scale sequencing project in cancer medicine are
crucial since cancer is a highly complex genetic disease
and the hereditary causative mutation of a combination
of mutations is only know for a very small number of fa-
milial cancers. As such, NGS approaches translated into
clinical practice have the potential to unravel some of
this genetic complexity. Such knowledge can provide
genetic counselors with information that is required to
feed clinical decision-support systems when selectingFigure 4 The Challenge: Selection of the suitable drug In
conventional medical approaches, valuable drugs go to
unsusceptible patients. (Spear et al., 2001).the best possible treatment plan and therapeutic inter-
vention for an individual patient. Also, such data would
provide the information necessary to inform family
members of potential risks of a disease and to ensure
that these family members have access to the most ap-
propriate screening programs and preventions. The
knowledge gained also leads to the development of more
preventive rather than curative therapies.
Economic aspects
Along with the discussions of translating genomic know-
ledge into clinical practice come considerations of the
economic value, namely careful assessments of benefits,
risks and costs (Collins et al., 2003; Haga and Burke
2004). With regards to the cost-effectiveness of different
genomic screening strategies, more evidence is needed
since most analyses so far do not take the impact of test-
ing on quality of life into account. Assessments should
consider the complexity for screening for genomic aber-
rations, including the development of reliable algorithms
for integrated data analysis. Incorporating subgroups or
family members of affected patients, should also be con-
sidered. To assess the value of personalized medicine, it
is important to define approaches that consider both
diagnostic tests and the treatment with drugs. Genome-
based diagnostic tests should elucidate whether the
detected mutations are relevant to the given phenotype
and if this phenotype can be linked to clinical predic-
tions. From a market’s perspective, the diagnostic market
represents a large and fast growing opportunity for
NGS, much greater than the currently addressed life sci-
ence research market, which is mostly driven by bio-
pharmaceutical research and development (R&D) or
government funding. However, the diagnostics market
also entails much larger regulatory and reimbursement
hurdles. Thus, to successfully translate NGS-based sys-
tems into clinical practice, it will be crucial to develop
valuable, user-friendly, reliable, and cost-effective diag-
nostic tests. To facilitate routine testing in clinical prac-
tice and laboratories, the market is demanding cost
effective and simple-to-perform tests that have cleared
the many regulatory hurdles. Also, automation is playing
a key role in the development of diagnostic tests that are
easier and less expensive to operate. Given the re-
emergence of infectious threats, viz. multidrug-resistant
TB, new strains of HIV or H1N1, infectious disease test-
ing represents a large portion of the current market for
molecular diagnostics. Here, pharmacogenomics will
likely be the most immediate new opportunity in the
field and many pharmaceutical companies invest signifi-
cantly in pharmacogenomics in anticipation of shaving
years off the drug discovery and approval process, bring-
ing potentially lucrative drugs to market much sooner
(Constance, 2010).
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lecular oncology diagnostics sector is expected to grow
at a compound annual growth rate (CAGR) of approx.
18% per annum; through 2015, the molecular diagnostics
market will grow at double-digit pace, achieving an over-
all 14% CAGR to meet increasing demand for persona-
lized medicine. Key areas of growth include not only
oncology an infectious diseases, but also genetic testing
and biobanking with a wide variety of drugs in late
preclinical and early clinical trials being targeted to
disease-specific gene and protein defects that will re-
quire co-approval of diagnostic and therapeutic products
by the regulatory authorities.
Ethical aspects
Ethical issues come along with the advancements and
progression of translational genomics and the debate is
mostly about discrimination, confidentiality and data se-
curity or informed consent. Unlike most diagnostic tests,
whole genome sequencing allows the identification of an
individual and related family members. Thus, concerns
regarding data security and privacy are raised and access
to genomic patient data must be restricted to the use in
clinical practice.
As discussed, there are both substantial challenges and
benefits in translating genetic results about disease sus-
ceptibilities or genomic data into clinical practice. Stud-
ies on individual (cancer) genomes and genetic
susceptibility produce large volumes of biomedical data
on a wide range of phenotypes. The impact of genetic
data can extend well beyond clinical utility as there may
be emotional, rather than practical benefits and risks of
genetic risk information if provided to a patient; the
emotional meaning may be more relevant for very large
amounts of genetic information and information on sus-
ceptibility and risk, rather than prediction/diagnosis and
people may react very differently to this kind of data,
based on personality/coping strategy and the context of
the information. Thus, patients should be encouraged to
consider the range of results, how they might cope, and
the range of possible actions/reactions before performing
NGS-based diagnostic tests. As genetic studies on sus-
ceptibility to disease proliferate, it s necessary to demand
replication and understanding of population attributable
risks of significant findings. As patients and consumers
seek out genetic profiling and will ask for such profiles,
physicians need to understand the clinical validity and
limitations of the data for making health-related deci-
sions and should be trained to interpret the complex
results of personal genomic sequencing data.
We need well-designed studies about how patients/
consumers are affected by genetic data, especially large
amounts of data, in order to understand the risk and
benefits.Another aspect is the equality of access in relation to
further delivery of personalized treatments since novel
drugs in this particular field are very expensive and ubi-
quitous reimbursement schemes are not in place in most
countries yet.
Conclusions
At present, little is known about the use, preferences,
and value of genome-based approaches in personalized
medicine (Khoury et al., 2006). Further research is
required to overcome the challenges associated with the
translation of genomic knowledge into clinical decision-
making in terms of patient data, testing procedures, al-
gorithm development and the use of such information in
therapy planning.
As the NGS technologies are advancing, it is very
likely that these technologies will be translated into the
clinical labs and hospitals and not only guide the treat-
ment of patients who have failed to respond to first-line
therapies. With these advancements, a better under-
standing of human cancer genomes comes along. The
comprehensive analysis of such genomes in healthy and
diseased samples will generate comprehensive genomic,
epigenomic and transcriptomic data present in diverse
human tumors and the structural and functional analysis
of these data will allow for the development of novel
biomarker-based diagnostics, innovative therapeutics
and will guide clinical trials. The main focus has been
on known cancer pathways so far, but the full applica-
tion of these approaches will lead to the identification of
novel pathways and players that maintain the malignant
state, thus providing the framework to develop novel
diagnostics and therapeutics. However, collecting accur-
ate clinical information on tumor samples remains a
challenging task and often samples are associated with
incomplete annotation. Challenges associated with
bringing NGS-based data into the clinic are not only sci-
entific, like accounting for the genetic heterogeneity
within tumors, but are also operational and legal, in
terms of patient consent and data protection. In the fu-
ture, NGS technologies will further advance, thus allow-
ing the analysis of patterns of genetic heterogeneity on
the single-cell level. Integrative analyses will then be able
to determine how the heterogeneity affects tumor initi-
ation, progression, recurrence or a patient’s response to
treatment. Another step is to make genomic data avail-
able in useful formats that can be applied to clinical de-
cision-support, selecting from treatment options and to
plan therapeutic interventions. The ability to applying
advanced genomic technologies prospectively in
patients, together with integrated functional analyses,
will provide a deeper understanding of tumor biology,
and will also facilitate the selection of the best available
treatment option for each and every individual patient.
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